STAT+: Pharmalittle: We’re reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more

The U.S. government is funding clinical trials for the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder. This initiative was made possible by an executive order signed by President Trump in April, which allocated $50 million for the federal ibogaine research. The FDA has opened a public docket to gather feedback on various aspects of the trials, including trial design, dose selection, patient eligibility, safety monitoring, and study-stopping rules.

AstraZeneca has expanded its presence in the U.S. market by opening a new R&D center in Cambridge, Massachusetts, as part of a $1 billion investment program in the state. The facility spans 570,000 square feet across 18 stories in the Kendall Square area, which is home to a dense cluster of biotech companies.